Impulse News

– „I feel like I have won the lottery!“

Ulla Magnusson, today 80 years old, was implanted with an Optimizer® device for cardiac contractility modulation treatment of her chronic heart failure at Karolinska university hospital two years ago. Ulla describes how fatigue and shortness of breath started to take over her life about 5 years ago and how it affected her everyday living: “It […]

Mehr dazu

New device based treatment for patients with Chronic Heart Failure now available in the Nordic region

Cardiac contractility modulation (CCM™) is a device based therapy which EU Studies have shown to be an effective treatment option for patients with Chronic Heart Failure (CHF). CCM™ therapy will now be made available to patients in the Nordic region by consultation with their treating doctors. An estimated 250 000 individuals in Sweden suffer from […]

Mehr dazu

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study.

Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm Continued Access evaluation of the company’s Cardiac Contractility Modulation (CCM™) device. Impulse Dynamics proprietary CCM™ technology delivers non-excitatory electric pulses to the cardiac muscle with the […]

Mehr dazu

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM™) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round. The equity financing round was led by Goldstone Investment, a global investment company belonging to the Chinese conglomerate CITIC Securities, […]

Mehr dazu

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017 — Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM™) signals delivered by the implantable Optimizer® […]

Mehr dazu
Seite 1 von 912345...Letzte »